Virax Biolabs Group Ltd

Listed Company
VRAXCIK 0001885827NasdaqNon-AcceleratedEmerging GrowthIn Vitro & In Vivo Diagnostic SubstancesE9KYFY ends Mar 31
Period
FY 2025
Revenue
Net Income
$-6.07M
Total Assets
$6.43M
Equity
Shares Out
4.34M
Op. Cash Flow

Business

Virax Biolabs Group Ltd is a holding company that conducts operations through subsidiaries developing and commercializing in‑vitro diagnostics focused on T cell immunology and viral disease management. It offers T cell diagnostic assays and an immunology profiling platform under the ViraxImmune brand, and distributes third‑party IVD test kits via ViraxClear and ViraxVet. Its key business segments include ViraxImmune (R&D and IVD development) and distribution brands (ViraxClear/ViraxVet). The company markets products primarily in the United Kingdom, North America and the European Union through healthcare providers, laboratories, pharmacies and distributor channels.

Summary from filing dated 2025-07-02

Financials

Latest annual snapshot (FY2025, period end 2025-03-31). Full statement history unavailable for this entity.

Revenue
Net income$-6.07M
Total assets$6.43M
Total liabilities$964.8K
Stockholders' equity
Operating cash flow

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro